Protocol for an economic evaluation of a tele-neurologic intervention alongside a stepped wedge randomised controlled trial (NeTKoH). 2023

Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany. ana.goncalves@charite.de.

BACKGROUND A significant and growing portion of the global burden of diseases is caused by neurological disorders. Tele-neurology has the potential to improve access to health care services and the quality of care, particularly in rural and underserved areas. The economic evaluation of the stepped wedge randomised controlled trial NeTKoH aims to ascertain the cost-effectiveness and cost-utility regarding the effects of a tele-neurologic intervention in primary care in a rural area in Germany. METHODS This protocol outlines the methods used when conducting the trial-based economic evaluation of NeTKoH. The outcomes used in our economic analysis are all prespecified endpoints of the NeTKoH trial. Outcomes considered for the cost-utility and cost-effectiveness analyses will be quality-adjusted life years (QALYs) derived from the EQ-5D-5L, proportion of neurologic problems being solved at the GP's office (primary outcome), hospital length-of-stay and number of hospital stays. Costs will be prospectively collected during the trial by the participating statutory health insurances, and will be analysed from a statutory health insurance perspective within the German health care system. This economic evaluation will be reported complying with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. CONCLUSIONS This within-trial economic evaluation relaying the costs and outcomes of an interdisciplinary tele-consulting intervention will provide high-quality evidence for cost-effectiveness and policy implications of a tele-neurological programme, including the potential for application in other rural areas in Germany or other jurisdictions with a comparable health system. BACKGROUND German Clinical Trials Register (DRKS00024492), date registered: September 28, 2021.

UI MeSH Term Description Entries
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005858 Germany A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. The capital is Berlin.
D006761 Hospitals Institutions with an organized medical staff which provide medical care to patients. Hospital
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000094703 Cost-Effectiveness Analysis A method of comparing the cost of a program with its expected outcomes that are qualitative in nature. Cost effectiveness compares alternative ways to achieve a specific set of results. Cost Effectiveness,Cost Effectiveness Ratio,Analysis, Cost-Effectiveness,Cost Effectiveness Analysis,Cost Effectiveness Ratios,Effectiveness Ratio, Cost,Effectiveness, Cost,Ratio, Cost Effectiveness
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D057189 Checklist Aid for consistent recording of data such as tasks completed and observations noted. Checklists

Related Publications

Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
May 2018, BMJ open,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
February 2008, Implementation science : IS,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
January 2021, PharmacoEconomics,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
April 2023, BMJ open,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
May 2017, BMJ open,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
January 2018, Orphanet journal of rare diseases,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
January 2019, BMJ open,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
May 2015, BMC public health,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
January 2018, BMJ open,
Ana S Oliveira Gonçalves, and Imke Mayer, and Ricarda S Schulz, and Agnes Flöel, and Felix von Podewils, and Anselm Angermaier, and Kerstin Wainwright, and Tobias Kurth, and
May 2019, JMIR mental health,
Copied contents to your clipboard!